IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by CIBC Asset Management Inc

CIBC Asset Management Inc grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 3.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 26,366 shares of the company's stock after purchasing an additional 788 shares during the period. CIBC Asset Management Inc's holdings in IDEXX Laboratories were worth $10,901,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the business. Chicago Partners Investment Group LLC grew its holdings in IDEXX Laboratories by 16.7% during the third quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock worth $340,000 after acquiring an additional 96 shares during the period. National Pension Service grew its stake in shares of IDEXX Laboratories by 7.3% during the 3rd quarter. National Pension Service now owns 185,972 shares of the company's stock worth $93,957,000 after purchasing an additional 12,647 shares during the period. Insight Wealth Strategies LLC increased its holdings in shares of IDEXX Laboratories by 230.5% in the 4th quarter. Insight Wealth Strategies LLC now owns 10,096 shares of the company's stock valued at $4,174,000 after purchasing an additional 7,041 shares in the last quarter. Larson Financial Group LLC lifted its stake in shares of IDEXX Laboratories by 17,238.5% in the third quarter. Larson Financial Group LLC now owns 2,254 shares of the company's stock valued at $1,139,000 after purchasing an additional 2,241 shares during the period. Finally, Quest Partners LLC grew its position in IDEXX Laboratories by 4,059.4% during the third quarter. Quest Partners LLC now owns 2,870 shares of the company's stock worth $1,450,000 after buying an additional 2,801 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Up 0.4 %

NASDAQ:IDXX traded up $1.90 on Thursday, reaching $452.89. The stock had a trading volume of 615,712 shares, compared to its average volume of 704,594. The firm's fifty day moving average is $431.19 and its two-hundred day moving average is $452.42. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. The company has a market cap of $37.09 billion, a price-to-earnings ratio of 42.45, a P/E/G ratio of 3.38 and a beta of 1.37. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $583.39.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of research reports. Barclays lifted their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an "overweight" rating in a research report on Tuesday, February 4th. Morgan Stanley reduced their price objective on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. StockNews.com lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Wednesday, February 5th. Bank of America raised their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Finally, Piper Sandler boosted their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and an average target price of $533.75.

Insiders Place Their Bets

In related news, EVP George Fennell sold 9,986 shares of the business's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Sophie V. Vandebroek sold 344 shares of IDEXX Laboratories stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total transaction of $144,631.36. Following the completion of the transaction, the director now owns 905 shares in the company, valued at approximately $380,498.20. This trade represents a 27.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 13,330 shares of company stock valued at $6,161,276 in the last quarter. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.